Literature DB >> 16397372

Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.

Toshio Nishikimi1, Hiroaki Matsuoka.   

Abstract

Among the GTP-binding proteins, Rho is known to function as a molecular switch in various cellular functions. Among the Rho effectors, the cellular function and signal transduction of Rho-kinase have been extensively studied. However, information about its in vivo functions is still limited. With the recent development of a specific Rho-kinase inhibitor such as Y-27632 and fasudil, the understanding of the role of the Rho/Rho-kinase pathway in vitro and in vivo has advanced. However, to date, there have been few studies investigating the role of Rho-kinase in renal disease. Recent studies have shown that Rho-kinase inhibitor significantly attenuated the tubulointerstitial fibrosis in kidney induced by unilateral ureteral obstruction. However, there have been few studies investigating the role of the Rho/Rho-kinase pathway in hypertensive glomerular sclerosis. In this review, we described the role of the Rho/Rho-kinase pathway in the progression of renal glomerulosclerosis in several forms of hypertensive rats. Our results suggest that chronic inhibition of the Rho-kinase pathway may be a new therapeutic approach for hypertensive glomerulosclerosis. Our results also suggest that the mechanism of the renoprotective effect of Rho-kinase inhibitor is partly mediated via inhibition of extracellular matrix gene expression, monocytes/macrophages infiltration, oxidative stress, and upregulation of eNOS gene expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397372     DOI: 10.1254/jphs.fmj05003x5

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  17 in total

Review 1.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis.

Authors:  Qiang Ding; Tracy Luckhardt; Louise Hecker; Yong Zhou; Gang Liu; Veena B Antony; Joao deAndrade; Victor J Thannickal
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 2.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

3.  Evaluation of Rho-kinase activity in mice brain using N-[11C]methyl-hydroxyfasudil with positron emission tomography.

Authors:  Junko Taniguchi; Chie Seki; Hiroyuki Takuwa; Hiroshi Kawaguchi; Yoko Ikoma; Masayuki Fujinaga; Iwao Kanno; Ming-Rong Zhang; Satoshi Kuwabara; Hiroshi Ito
Journal:  Mol Imaging Biol       Date:  2013-10-24       Impact factor: 3.488

4.  Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.

Authors:  Liming Wang; Mathew J Ellis; Timothy A Fields; David N Howell; Robert F Spurney
Journal:  Kidney Blood Press Res       Date:  2008-03-27       Impact factor: 2.687

5.  Rac1 promotes TGF-beta-stimulated mesangial cell type I collagen expression through a PI3K/Akt-dependent mechanism.

Authors:  Susan C Hubchak; Erin E Sparks; Tomoko Hayashida; H William Schnaper
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-02

6.  A Rho-kinase inhibitor, fasudil, attenuates progressive glomerulosclerosis induced by daunorubicin in rats.

Authors:  Bingqing Deng; Xiao Yang; Zhonghua Zhu; Chun Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

7.  A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules.

Authors:  Ha Won Lee; Samia Q Khan; Mohd Hafeez Faridi; Changli Wei; Nicholas J Tardi; Mehmet M Altintas; Hatem A Elshabrawy; Steve Mangos; Kevin L Quick; Sanja Sever; Jochen Reiser; Vineet Gupta
Journal:  J Am Soc Nephrol       Date:  2015-04-09       Impact factor: 10.121

8.  Mechanisms of the proteinuria induced by Rho GTPases.

Authors:  Liming Wang; Mathew J Ellis; Jose A Gomez; William Eisner; Walter Fennell; David N Howell; Phillip Ruiz; Timothy A Fields; Robert F Spurney
Journal:  Kidney Int       Date:  2012-01-25       Impact factor: 10.612

9.  The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration.

Authors:  Anna Tsapara; Phillip Luthert; John Greenwood; Caroline S Hill; Karl Matter; Maria S Balda
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

10.  Distinct mesenchymal alterations in N-cadherin and E-cadherin positive primary renal epithelial cells.

Authors:  Christof Keller; Sven Kroening; Jonathan Zuehlke; Frank Kunath; Bettina Krueger; Margarete Goppelt-Struebe
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.